423 related articles for article (PubMed ID: 34049893)
1. Sclerosing cholangitis in a patient treated with nivolumab.
Talbot S; MacLaren V; Lafferty H
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34049893
[TBL] [Abstract][Full Text] [Related]
2. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
Yoshikawa Y; Imamura M; Yamaoka K; Kosaka Y; Murakami E; Morio K; Fujino H; Nakahara T; Okamoto W; Yamauchi M; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Fujitaka K; Arihiro K; Hattori N; Chayama K
Clin J Gastroenterol; 2021 Feb; 14(1):283-287. PubMed ID: 33200345
[TBL] [Abstract][Full Text] [Related]
3. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
[TBL] [Abstract][Full Text] [Related]
4. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
McClure T; Cui W; Asadi K; John T; Testro A
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32912846
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.
Sato K; Hayashi M; Abe K; Fujita M; Takahashi A; Ohira H
Clin J Gastroenterol; 2020 Dec; 13(6):1310-1314. PubMed ID: 32643124
[TBL] [Abstract][Full Text] [Related]
6. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
[No Abstract] [Full Text] [Related]
7. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Onoyama T; Takeda Y; Yamashita T; Hamamoto W; Sakamoto Y; Koda H; Kawata S; Matsumoto K; Isomoto H
World J Gastroenterol; 2020 Jan; 26(3):353-365. PubMed ID: 31988594
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis.
Kono M; Sakurai T; Okamoto K; Masaki S; Nagai T; Komeda Y; Kamata K; Minaga K; Yamao K; Takenaka M; Watanabe T; Nishida N; Kudo M
Intern Med; 2019 May; 58(9):1263-1266. PubMed ID: 30626829
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-Induced Secondary Sclerosing Cholangitis with Deterioration Despite Immunosuppression.
Anderson B; Dawe DE
J Thorac Oncol; 2019 Sep; 14(9):e205-e206. PubMed ID: 31445738
[No Abstract] [Full Text] [Related]
12. Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports.
Yacoub H; Ben Azouz S; Hassine H; Debbabi H; Cherif D; Ghayeb F; Boukriba S; Kchir H; Maamouri N
J Med Case Rep; 2023 Apr; 17(1):169. PubMed ID: 37106413
[TBL] [Abstract][Full Text] [Related]
13. Sclerosing cholangitis associated with hypereosinophilic syndrome.
Ichikawa N; Taniguchi A; Akama H; Ishiguro H; Kurihara T; Terai C; Hara M; Kashiwazaki S
Intern Med; 1997 Aug; 36(8):561-4. PubMed ID: 9260773
[TBL] [Abstract][Full Text] [Related]
14. Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture.
Fracchia M; Soubrane O; Houssin D; Galatola G
Ital J Gastroenterol; 1995; 27(8):430-5. PubMed ID: 8775469
[TBL] [Abstract][Full Text] [Related]
15. [A case of pembrolizumab-induced sclerosing cholangitis that was responsive to high-dose steroid therapy].
Nagasawa S; Miyazaki M; Morita Y; Tanaka K; Yada M; Masumoto A; Motomura K
Nihon Shokakibyo Gakkai Zasshi; 2021; 118(10):981-990. PubMed ID: 34629349
[TBL] [Abstract][Full Text] [Related]
16. Resolution of radiographic abnormalities with ursodeoxycholic acid therapy of primary sclerosing cholangitis.
Lebovics E; Salama M; Elhosseiny A; Rosenthal WS
Gastroenterology; 1992 Jun; 102(6):2143-7. PubMed ID: 1587436
[TBL] [Abstract][Full Text] [Related]
17. Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid.
Lee YM; Kaplan MM
Curr Gastroenterol Rep; 1999; 1(1):38-41. PubMed ID: 10980925
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
20. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period.
Stiehl A; Walker S; Stiehl L; Rudolph G; Hofmann WJ; Theilmann L
J Hepatol; 1994 Jan; 20(1):57-64. PubMed ID: 8201224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
